Dupixent Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age With Eosinophilic Esophagitis

Media coverage

• Title	-Sanofi - Dupixent Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis
  Media name/outlet	M2 PressWIRE
  Country/Territory	United States
  Date	23/10/23
  Persons	Mirna Chehade

• Title	-REGENERON PHARMACEUTICALS - DUPIXENT PHASE 3 RESULTS SHOW SUSTAINED EFFICACY FOR UP TO ONE YEAR IN CHILDREN 1 TO 11 YEARS OF AGE WITH EOSINOPHILIC ESOPHAGITIS
  Media name/outlet	M2 PressWIRE
  Country/Territory	United States
  Date	23/10/23
  Persons	Mirna Chehade

• Title	-Sanofi - Dupixent Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	23/10/23
  Persons	Mirna Chehade

• Title	-REGENERON PHARMACEUTICALS - DUPIXENT PHASE 3 RESULTS SHOW SUSTAINED EFFICACY FOR UP TO ONE YEAR IN CHILDREN 1 TO 11 YEARS OF AGE WITH EOSINOPHILIC ESOPHAGITIS
  Media name/outlet	ENP Newswire
  Country/Territory	United Kingdom
  Date	23/10/23
  Persons	Mirna Chehade

• Title	Dupixent Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age With Eosinophilic Esophagitis
  Media name/outlet	Targeted News Service
  Country/Territory	United States
  Date	22/10/23
  Persons	Mirna Chehade